Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Scion Cardio-Vascular produces the Clo-Sur Plus P.A.D., a topical hemostatic pad approved by the FDA for rapid bleeding control and antibacterial wound management for a variety of indications. In vitro data show antibacterial and antifungal activity though clinical significance of this feature is unproven[3].
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Scion Cardio-Vascular.